L 163540
Latest Information Update: 24 Jan 2008
Price :
$50 *
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 08 Apr 1998 Investigation in Somatotropin deficiency in USA (Unknown route)